Algernon Pharmaceuticals Inc (AGNPF)

[medchem]

As our kind friendly moderators have already mentioned, to be clear, this is a NMDA-antagonist that is suspected to modulate the immune response and decrease acute lung injury. It is a known neuroprotective agent and I have posted literature supporting this claim. NMDA receptors sit on the post-synaptic neuronal membrane and are regulators of the hyperexcitability response. They can be involved in neuronal death. Antagonizing this is advantageous. There role has been explored in idiopathic pulmonary fibrosis where our ifenprodil outpeformed the best big pharma has to offer in decreasing cough frequency and the phase 2 trial is planned and ethics application is submitted in australia (where we get a tax rebate on 40% of the trial fees and where our partner Novotech lives). Novotech is the CRO who will be conducting our trials and is a world leader. They are also invested in algernon, just like Alpha North Asset management.

To be clear, NMDA-antognism is a TREATMENT. Not a vaccine. Vaccines prevent illness. Treatments help those who are already sick.